Schedule test pg

NB: TCT TV not added yet
 * Potential midday conflict on Tuesday

Click on Date for Detailed Schedule
Sunday October 12, 2008

Monday October 13, 2008

Tuesday October 14, 2008

Wednesday October 15, 2008

Thursday October 16, 2008

12:40 PM
12:40 -2:00 PM
 * Topic: Interventional Strategies and Adjunct Pharmacology in ACS and AMI, Part I: Unstable Angina and NSTEMI. Session II Chest Pain Evaluation and Management Strategies
 * Room: 147 B
 * Role: Moderator

1:40 - 2:00 PM
 * Topic: Interventional Strategies and Adjunct Pharmacology in ACS and AMI, Part I: Unstable Angina and NSTEMI. Session II Chest Pain Evaluation and Management Strategies
 * Details: Moderated Roundtable Discussion and Audience Q&A
 * Room: 147 B
 * Role: Panel Moderator

5:22 PM
5:22 – 5:32 PM
 * Topic: Interventional Strategies and Adjunct Pharmacology in ACS and AMI, Part I: Unstable Angina and NSTEMI. ACS Session IV: Antiplatelet and Antithrombin Decisions in NSTE-ACS: Data-driven Debates
 * Details: Thienopyridine Decisions: Clopidogrel vs. Prasugrel in NSTE-ACS? Prasugrel for Most: Preserve the Myocardium, and Keep Stents from Thrombosing!
 * Room: 147 B
 * Role: Lecturer

5:52 PM
5:52 – 6:02 PM
 * Topic: Interventional Strategies and Adjunct Pharmacology in ACS and AMI, Part I: Unstable Angina and NSTEMI. ACS Session IV: Antiplatelet and Antithrombin Decisions in NSTE-ACS: Data-driven Debates
 * Details: Thienopyridine Decisions: Clopidogrel vs. Prasugrel in NSTE-ACS? Roundtable Discussion, and Questions from the Erudite Panel and Audience
 * Room: 147 B
 * Role: Discussant

10:28 AM
10:28-10:40 AM
 * Topic: The DES Summit: Dual Anti-Platelet Use Considerations
 * Details: Other Important Antiplatelet Agents. Prasugrel – A Potent Newcomber: Optimizing Use to Reduce Stent Thrombosis without Increasing Bleeding!
 * Room: Ballroom C
 * Role: Lecturer

10:40 AM
10:40 – 10:52 AM
 * Topic: The DES Summit: Dual Anti-Platelet Use Considerations
 * Details: Other Important Anti-Platelet Agents. Discussion with Audience Q&A
 * Room: Ballroom C
 * Role: Discussant

10:30 AM
10:30 – 11:00 AM
 * Topic: Main Arena I Plenary Sessions 3: PCI Controversies I
 * Details: The Appropriate Utilization of Antithrombotic and Antiplatelet Therapies
 * Room: Ballroom – Third Floor
 * Role: Discussant

1:06 PM
1:06 - 1:11 PM
 * Topic: Controversies in Adjunct Pharmacology: Agenda
 * Details: Upstream Drug Initiation in ACS - Impact on Clinical and Angiographic Outcomes
 * Room: 201
 * Role: Lecturer

1:11 PM
1:11 - 1:14 PM
 * Topic: Controversies in Adjunct Pharmacology: Agenda
 * Details: Audience Q&A
 * Room: 201
 * Role: Case Discussant

1:22 PM

 * 1:22 - 1:42 PM
 * Topic: Controversies in Adjunct Pharmacology: Agenda
 * Details: Discussion with Audience Q&A
 * Room: 201
 * Role: Panel Discussant

3:05 PM
3:05 - 3:30 PM Hot Topic 2: ACS Controversies: Adjunct Pharmacology and Conservative vs Invasive Approach
 * Topic: Exploring the Guidelines: Evidence Based Medicine Review and Debates
 * Details: Roundtable Discussion with Audience Q&A: Are the guidelines consistent with clinical practice and the latest clinical trial results?
 * Room: 209 ABC
 * Role: Disucussant

8:40 AM
8:40 - 8:55 AM
 * Topic: Coronary Theater - II: Focus on Interventional Pharmacology
 * Details: Upstream and Downstream Use of Glycoprotein IIb/IIIa Inhibitors: Integrating the Latest Clinical Trial Results
 * Room: Coronary Theater, Lower Level
 * Role: Lecturer

12:27 PM
12:27 - 12:30 PM
 * Topic: Main Arena II: Plenary Session 13: "First Report" Randomized Trials & Registries II
 * Details: Critique and Clinical Perspectives
 * Room: Ballroom- Third Level
 * Role: Critical Commentary

12:30 PM
12:30 - 2:30 PM
 * Press conferences and TCT-TV Interviews
 * Room: TCT TV Studio

9:50 AM
9:50 - 11:05 AM Session III: Current Antithrombin Choices for PCI (elective, NSTEMI and STEMI)
 * Topic: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Antithrombins, Xa Inhibitors and Emerging Agents
 * Room: 145 AB
 * Role: Moderator

10:50 - 11:05 AM Session III: Current Antithrombin Choices for PCI (elective, NSTEMI and STEMI)
 * Topic: Antithrombin Alternatives: Low Molecular Weight Heparins, Direct Antithrombins, Xa Inhibitors and Emerging Agents
 * Details: Moderated Roundtable Discussion with Audience Q&A
 * Room: 145 AB
 * Role: Panel Moderator

12:30 PM
12:30 - 2:30 PM
 * Press conferences and TCT-TV Interviews
 * Room: TCT TV Studio